Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study
W de Jager, EPAH Hoppenreijs, NM Wulffraat… - Annals of the …, 2007 - ard.bmj.com
Background: Juvenile idiopathic arthritis (JIA) consists of a heterogeneous group of disorders
with, for the most part, an unknown immunopathogenesis. Although onset and disease …
with, for the most part, an unknown immunopathogenesis. Although onset and disease …
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
…, W Armbrust, EPAH Hoppenreijs… - Annals of the …, 2009 - ard.bmj.com
Objective: We undertook an observational study to obtain a complete overview of the long-term
effectiveness and safety of etanercept in patients with different juvenile idiopathic arthritis …
effectiveness and safety of etanercept in patients with different juvenile idiopathic arthritis …
The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis
…, R ten Cate, EPAH Hoppenreijs… - Annals of the …, 2012 - ard.bmj.com
Background Analysis of myeloid-related protein 8 and 14 complex (MRP8/14) serum
concentrations is a potential new tool to support the diagnosis of systemic-onset juvenile idiopathic …
concentrations is a potential new tool to support the diagnosis of systemic-onset juvenile idiopathic …
Factors associated with treatment response to etanercept in juvenile idiopathic arthritis
…, W Armbrust, R ten Cate, EPAH Hoppenreijs… - Jama, 2011 - jamanetwork.com
Context Since the introduction of biologic therapies, the pharmacological treatment approach
for juvenile idiopathic arthritis (JIA) has changed substantially, with achievement of inactive …
for juvenile idiopathic arthritis (JIA) has changed substantially, with achievement of inactive …
Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis
…, W Armbrust, EPAH Hoppenreijs… - Annals of the …, 2007 - ard.bmj.com
Objective: To assess the effect of measles, mumps and rubella (MMR) vaccination on
disease activity in children with juvenile idiopathic arthritis (JIA). Methods: A retrospective …
disease activity in children with juvenile idiopathic arthritis (JIA). Methods: A retrospective …
[HTML][HTML] MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis
…, KM Dolman, EPAH Hoppenreijs… - Arthritis Research & …, 2015 - Springer
Introduction Approximately 30 % of juvenile idiopathic arthritis (JIA) patients fail to respond
to anti-TNF treatment. When clinical remission is induced, some patients relapse after …
to anti-TNF treatment. When clinical remission is induced, some patients relapse after …
[PDF][PDF] Galectin‐9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation
…, SSM Kamphuis, EPAH Hoppenreijs… - Arthritis & …, 2019 - Wiley Online Library
Objective Objective evaluation of disease activity is challenging in patients with juvenile
dermatomyositis ( DM ) due to a lack of reliable biomarkers, but it is crucial to avoid both under‐ …
dermatomyositis ( DM ) due to a lack of reliable biomarkers, but it is crucial to avoid both under‐ …
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register
…, SJ Vastert, R ten Cate, EPAH Hoppenreijs… - Annals of the …, 2015 - ard.bmj.com
Background Treatment of juvenile idiopathic arthritis (JIA) has changed dramatically since
the introduction of biological agents in 1999. Objective To evaluate trends in prescription …
the introduction of biological agents in 1999. Objective To evaluate trends in prescription …
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register
…, J Anink, R Ten Cate, EPAH Hoppenreijs… - Annals of the …, 2013 - ard.bmj.com
Objective To evaluate the effectiveness and safety of switching to a second or third biological
agent in juvenile idiopathic arthritis (JIA) after etanercept failure. Methods The Arthritis and …
agent in juvenile idiopathic arthritis (JIA) after etanercept failure. Methods The Arthritis and …
Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis—data from the Dutch arthritis and biologicals in children register, 1999–2010
…, W ARMBRUST, EPAH HOPPENREIJS… - The Journal of …, 2011 - jrheum.org
Objective. To evaluate the effectiveness and safety of biological agents in children with
enthesitis-related arthritis (ERA). Methods. All patients with ERA in whom a biological agent was …
enthesitis-related arthritis (ERA). Methods. All patients with ERA in whom a biological agent was …